Home > Healthcare > Drug Device Combination > Uropathy Treatment Market

Uropathy Treatment Market Trends

Report ID: GMI9581
Published Date: May 2024
Report Format: PDF

Download Free Sample

Uropathy Treatment Market Trends

Uropathy can be caused by various factors including kidney stones, bladder stones, blood clots, and certain types of cancer such as uterine, colon, and cervical cancer. The occurrence of urological problems with the nerves that supply the bladder can also lead to uropathy. These conditions drive the need for effective treatment options, thereby boosting the market growth.

According to a study published in Advances in Urology, kidney stone disease is a growing urological disorder affecting approximately 15% of the global population. It occurs more frequently in men aged 30-60 years, with around 7% of women and 13% of men developing a kidney stone during their lifetime. This rise in incidence surged the demand for kidney stone management which will increase the demand for treatment options.

Therefore, the rising incidence of urological disorders, cancer, combined with technological advancements in drainage procedures and innovations in urinary retention treatments such as extracorporeal shock wave lithotripsy, are the primary factors driving the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The uropathy treatment market size was valued at USD 4.7 billion in 2023 and is estimated to grow at 4.1% CAGR from 2024 – 2032, driven by the increasing incidence of urinary tract disorders, such as urinary tract infections (UTIs).

The hospitals end-use segment of the market will account for USD 1.8 billion by 2032, owing to specialized urology departments furnished with advanced technologies and staffed by skilled multidisciplinary teams.

U.S. uropathy treatment market size was USD 1.9 billion in 2023 and will grow rapidly through 2032, driven by the increasing prevalence of urological disorders, including the rising occurrence of urinary retention within the population.

Astellas Pharma Inc., B. Braun Melsungen AG, Becton, Dickinson, and Company, Boston Scientific Corporation, Cook Medical, Glaxo SmithKline Pharmaceuticals Ltd., Inceler Medikal Co. Ltd., KARL STORZ, Purdue Pharma, Olympus America, and Pfizer Inc. among others.